Clinical TrialID 5536
Accessibility to New Drugs Versus SOC in Sweden
NCT03684395
Anticoagulation
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 5536
- Evidence Id
- 5536
- Core Evidence Id
- 5536
- Source Clinical Trial Id
- 5518
- Herb2 Clinical Trial Id
- HBCT005518
- Nct Id
- NCT03684395
- Title
- Accessibility to New Drugs Versus SOC in Sweden
- Status
- Completed
- Phase
- Study Result
- No
- Study Condition
- Anticoagulation
- Study Type
- Observational
- Study Design
- Observational Model: |Time Perspective: p
- Intervention
- DRUG: DOACs: Rivaroxaban, Dabigatran, Apixaban|DRUG: Standard of care (Warfarin)
- Intervention Allocation
- Intervention Model
- Intervention Mask
- Intervention Purpose
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 68056
- Outcome Measure
- Correlation between socioeconomic factors and use of DOACs vs. Warfarin (as identified from the LISA database before the index date), Between 1 December 2011 and 31 December 2014; Socioeconomic factors: * Occupation * Education * Income * Family status * Immigrant status, approximately 3 years
- Sponsor Collaborator
- Bayer
- Funded By
- INDUSTRY
- Location
- Stockholm, Sweden
- Other Id
- 18984
- Start Date
- 2016-06-15
- Primary Completion Date
- 2017-06-30
- Completion Date
- 2017-06-30
- First Posted
- 2018-09-25
- Results First Posted
- Last Update Posted
- 2019-03-29
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT03684395
- Title Cn
- Title En
- Accessibility to New Drugs Versus SOC in Sweden
- Bilingual Status
- semi_complete